We believe that the obtained reduction in the frequency of seizures with a relatively favorable profile of adverse effects exerted by the studied drug, as well as the potentially beneficial effect of mTOR pathway inhibitors on various, also not related to the central nervous system, manifestations of tuberous sclerosis constitute sufficient justification for undertaking this type of therapeutic intervention. This evidence concerns the gene MTOR and tuberous sclerosis.